312 related articles for article (PubMed ID: 29663858)
1. Assessment of liver and cardiac iron overload using MRI in patients with chronic anemias in Latin American countries: results from ASIMILA study.
Cancado R; Watman NP; Lobo C; Chona Z; Manzur F; Traina F; Park M; Drelichman G; Zarate JP; Marfil L
Hematology; 2018 Oct; 23(9):676-682. PubMed ID: 29663858
[TBL] [Abstract][Full Text] [Related]
2. Assessing cardiac and liver iron overload in chronically transfused patients with sickle cell disease.
Badawy SM; Liem RI; Rigsby CK; Labotka RJ; DeFreitas RA; Thompson AA
Br J Haematol; 2016 Nov; 175(4):705-713. PubMed ID: 27507431
[TBL] [Abstract][Full Text] [Related]
3. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.
Inati A; Musallam KM; Wood JC; Sheikh-Taha M; Daou L; Taher AT
Eur J Haematol; 2009 Dec; 83(6):565-71. PubMed ID: 19737308
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study.
Aydinok Y; Porter JB; Piga A; Elalfy M; El-Beshlawy A; Kilinç Y; Viprakasit V; Yesilipek A; Habr D; Quebe-Fehling E; Pennell DJ
Eur J Haematol; 2015 Sep; 95(3):244-53. PubMed ID: 25418187
[TBL] [Abstract][Full Text] [Related]
5. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
6. Hepatic and cardiac and iron overload detected by T2* magnetic resonance (MRI) in patients with myelodisplastic syndrome: A cross-sectional study.
Mantovani LF; Santos FPS; Perini GF; Nascimento CMB; Silva LP; Wroclawski CK; Esposito BP; Ribeiro MSS; Velloso EDRP; Nomura CH; Kay FU; Baroni RH; Hamerschlak N; Schuster S
Leuk Res; 2019 Jan; 76():53-57. PubMed ID: 30572266
[TBL] [Abstract][Full Text] [Related]
7. Iron overload in adults with sickle cell disease who have received intermittent red blood cell transfusions.
Pack-Mabien A; Brown B; Herbert DE; Haynes J
J Am Assoc Nurse Pract; 2015 Oct; 27(10):591-6. PubMed ID: 25711464
[TBL] [Abstract][Full Text] [Related]
8. Pituitary iron and volume predict hypogonadism in transfusional iron overload.
Noetzli LJ; Panigrahy A; Mittelman SD; Hyderi A; Dongelyan A; Coates TD; Wood JC
Am J Hematol; 2012 Feb; 87(2):167-71. PubMed ID: 22213195
[TBL] [Abstract][Full Text] [Related]
9. Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment.
Porter JB; El-Alfy M; Viprakasit V; Giraudier S; Chan LL; Lai Y; El-Ali A; Han J; Cappellini MD
Eur J Haematol; 2016 Jan; 96(1):19-26. PubMed ID: 25691036
[TBL] [Abstract][Full Text] [Related]
10. Tissue iron evaluation in chronically transfused children shows significant levels of iron loading at a very young age.
Berdoukas V; Nord A; Carson S; Puliyel M; Hofstra T; Wood J; Coates TD
Am J Hematol; 2013 Nov; 88(11):E283-5. PubMed ID: 23861216
[TBL] [Abstract][Full Text] [Related]
11. Iron Overload in Patients With Heavily Transfused Sickle Cell Disease-Correlation of Serum Ferritin With Cardiac T2
Alkindi S; Panjwani V; Al-Rahbi S; Al-Saidi K; Pathare AV
Front Med (Lausanne); 2021; 8():731102. PubMed ID: 34760898
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox Decreases Liver Iron Concentration in Iron-Overloaded Patients with Myelodysplastic Syndromes, Aplastic Anemia and Other Rare Anemias.
Kohgo Y; Urabe A; Kilinç Y; Agaoglu L; Warzocha K; Miyamura K; Lim LC; Glaser S; Wang C; Wiktor-Jedrzejczak W
Acta Haematol; 2015; 134(4):233-42. PubMed ID: 26138856
[TBL] [Abstract][Full Text] [Related]
14. Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome.
de Montalembert M; Ribeil JA; Brousse V; Guerci-Bresler A; Stamatoullas A; Vannier JP; Dumesnil C; Lahary A; Touati M; Bouabdallah K; Cavazzana M; Chauzit E; Baptiste A; Lefebvre T; Puy H; Elie C; Karim Z; Ernst O; Rose C
PLoS One; 2017; 12(3):e0172147. PubMed ID: 28257476
[TBL] [Abstract][Full Text] [Related]
15. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
Cheong JW; Kim HJ; Lee KH; Yoon SS; Lee JH; Park HS; Kim HY; Shim H; Seong CM; Kim CS; Chung J; Hyun MS; Jo DY; Jung CW; Sohn SK; Yoon HJ; Kim BS; Joo YD; Park CY; Min YH;
Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging.
Wahidiyat PA; Liauw F; Sekarsari D; Putriasih SA; Berdoukas V; Pennell DJ
Hematology; 2017 Sep; 22(8):501-507. PubMed ID: 28218005
[TBL] [Abstract][Full Text] [Related]
17. Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors.
Tantiworawit A; Charoenkwan P; Hantrakool S; Choeyprasert W; Sivasomboon C; Sanguansermsri T
Int J Hematol; 2016 Jun; 103(6):643-8. PubMed ID: 27052211
[TBL] [Abstract][Full Text] [Related]
18. Myocardial and liver iron overload, assessed using T2* magnetic resonance imaging with an excel spreadsheet for post processing in Tunisian thalassemia major patients.
Ouederni M; Ben Khaled M; Mellouli F; Ben Fraj E; Dhouib N; Yakoub IB; Abbes S; Mnif N; Bejaoui M
Ann Hematol; 2017 Jan; 96(1):133-139. PubMed ID: 27730342
[TBL] [Abstract][Full Text] [Related]
19. [Value of magnetic resonance imaging T2* tests in detecting heart and liver iron overload in patients with β-thalassemia major].
Wu X; Jing Y; Pei F; Chen J; Feng X; He Y; Zhang Y; Li C
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Feb; 33(2):249-52. PubMed ID: 23443782
[TBL] [Abstract][Full Text] [Related]
20. Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy.
Brown K; Subramony C; May W; Megason G; Liu H; Bishop P; Walker T; Nowicki MJ
J Pediatr Hematol Oncol; 2009 May; 31(5):309-12. PubMed ID: 19415007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
